A major change of strategic direction awaits Sotio, PPF Group’s biotechnology company. In a field dominated by US and Swiss companies, rather than trying to make a breakthrough under its own steam Sotio will now look for partnerships with large pharmaceutical companies that could help fund the final and very expensive stage of clinical trials for new cancer drugs. As Sotio CEO Radek Špíšek told HN, there will be a two-pronged mission of establishing a base in the US and preparing for possible flotation on one of the stock exchanges over there.
Dear customer, we are sorry but your browser doesn't support all necessary features for good site view. Please switch to one of the modern browsers (Chrome, Safari, Firefox).
Latest
